Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 31, Number 3—March 2025
Research

Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA

Mark L. MeterskyComments to Author , Ashley J. Losier, David A. Fraulino, Theodore A. Warnock, Cara D. Varley, Angela M. Le, Kevin L. Winthrop, John R. McArdle, Salika M. Shakir, and Reeti Khare
Author affiliation: University of Connecticut School of Medicine, Farmington, Connecticut, USA (M.L. Metersky, D.A. Fraulino, J.R. McArdle); Yale University School of Medicine, New Haven, Connecticut, USA (A.J. Losier); Oregon Health and Science University, Portland, Oregon, USA (T.A. Warnock, C.D. Varley, A.M. Le, K.L. Winthrop); Portland State University, Portland (T.A. Warnock, C.D. Varley, K.L. Winthrop); University of Utah ARUP Laboratories, Salt Lake City, Utah, USA (S.M. Shakir); National Jewish Health, Denver, Colorado, USA (R. Khare)

Main Article

Table 1

Antimicrobial drug susceptibility testing results for 6 Mycobacterium nebraskense isolates from patients in Connecticut and Oregon, USA*

Drug MIC, μg/mL
CT-C3 CT-C5 CT-C6 OR-C1 OR-C2, pretreatment OR-C2, during treatment
TMP/SMX <0.25/4.75, S 4/76, R S NA NA NA
Doxycycline <0.12, S NA NA NA NA NA
Linezolid <1, S 2, S NA 2.0, S NA 64.0, R
Rifabutin <0.12, S 0.25, S S <0.25, S >0.5, R >8.0, R
Amikacin <1, S 2, S 8, S 4.0, I 4.0, I 16.0, R
Moxifloxacin 0.03, S 0.03, S S 0.25, S <0.5, S 16.0, S
Ciprofloxacin <0.12, S 1, S S 0.5, S 2.0, I 8.0, R
Clarithromycin <0.06, S 0.12, S 0.5, S 0.12, S <4.0, S 8.0, S
Minocycline 0.5, S 0.03, S NA NA NA NA
Rifampin 0.12, S 1, S S 0.5, S 1.0, S 16.0, R

*CT-C, Connecticut-case; I, intermediate; NA, not applicable; OR-C, Oregon-case; R, resistant; S, susceptible; TMP/SMX, trimethoprim-sulfamethoxazole.

Main Article

Page created: December 16, 2024
Page updated: February 28, 2025
Page reviewed: February 28, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external